SABCS 2022 | Sacituzumab govitecan effective for HR+ metastatic breast cancer regardless of Trop-2 status
Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, provides an overview of a biomarker analysis of the Phase III TROPiCS-02 (NCT03901339) trial that investigated the Trop-2 directed antibody-drug conjugate (ADC) sacituzumab govitecan (SG)nversus treatment of physician’s choice in participants with HR-positive/HER2-negeative metastatic breast cancer. Previous data of TROPiCS-02 demonstrated a progression-free survival (PFS) suggesting SG resulted in better PFS compared to chemotherapy, as well as data suggesting SG results in a statistically significant and clinically meaningful improvement in overall-survival (OS). At the San Antonio Breast Cancer Symposium (SABCS) 2022, biomarker data of TROPiCS-02 was presented with regard to Trop-2 expression and its association with outcome. Previous biomarker data from the Phase III ASCENT (NCT02574455) trial in patients with triple-negative breast cancer (TNBC) suggested all patients benefited from SG relative to chemotherapy irrespective of Trop-2 status. The biomarker analysis in TROPiCS-02 also suggests patients with HR-positive metastatic breast cancer benefit from SG relative to chemotherapy irrespective of Trop-2 status. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
